Bitbrain

Bitbrain operates at the intersection of neurotechnology, research instrumentation, wearable biosensing, and applied artificial intelligence. Its differentiation is breadth: the company combines EEG hardware, broader biosignal acquisition, eye tracking, experimental software, analytics, and custom engineering rather than focusing on only one sensor type or application. The portfolio includes dry, textile, water-based, and semi-dry EEG approaches, enabling use across laboratory, clinical, and more mobile environments. SennsLab supports experimental design and synchronization across more than 35 sensor modalities, while SennsMetrics addresses emotional, cognitive, and behavioral analysis. This gives Bitbrain a systems-level position for research organizations and commercial teams that need coordinated hardware, software, and services. Its likely competitive constraints are the technical complexity of multimodal deployments, the specialized nature of neurotechnology procurement, and competition from focused EEG, eye-tracking, and biosignal vendors. More evidence is needed to assess commercial scale, recurring software revenue, and adoption outside research-led use cases.

Bitbrain’s trajectory is characterized by product and capability expansion rather than documented financing or headcount growth. Founded in 2010 from the University of Zaragoza, the company has progressed from neurotechnology research into an integrated portfolio that covers wearable EEG, textile EEG, biosignal amplification, eye tracking, synchronization software, analytics, and custom product development. The range of hardware—from the 8-channel Air wearable and 12-channel Diadem system to higher-channel Versatile platforms—suggests an effort to serve both mobile studies and more instrumented research environments. Software such as SennsLite, SennsLab, and SennsMetrics extends the offering from data capture into experiment orchestration and interpretation. Custom development, including work from functional prototypes to production-scale products, may provide an additional route into specialized healthcare, marketing, education, and industrial applications. However, there are no disclosed funding rounds, valuation events, hiring figures, product-launch dates, or revenue indicators in the available profile. Consequently, the evidence supports sustained technical development and portfolio broadening, but not a quantified acceleration in commercial growth as of Oct 6, 2026.